Volume 4.43 | Nov 8

Prostate Cell News 4.43 November 8, 2013
Prostate Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Prostate Cell News on Twitter
Androgens Regulate Prostate Cancer Cell Growth via an AMPK-PGC-1a-Mediated Metabolic Switch
Researchers demonstrated that androgen receptor regulates prostate cancer cell growth via the metabolic sensor 5′-AMP-activated protein kinase, a kinase that classically regulates cellular energy homeostasis. [Oncogene] Abstract
New TeSR™-E8™ is Here For Feeder-Free Culture of Human ES Cells and iPS Cells
PUBLICATIONS (Ranked by impact factor of the journal)

TMPRSS2-ERG Gene Fusions Induce Prostate Tumorigenesis by Modulating MicroRNA miR-200c
Experimentation of prostate cancer (PCa) cells with ERG overexpression or knockdown demonstrated that ERG directly repressed miR-200c expression by physically binding to the erythroblast transformation-specific motif within its promoter. Consequently, miR-200c was downregulated in ERG-positive PCa, and miR-200c target gene expression was restored. [Oncogene] Abstract

Phosphoproteomic Profiling Identifies Focal Adhesion Kinase as a Mediator of Docetaxel Resistance in Castrate Resistant Prostate Cancer
Using quantitative mass spectrometry-based phosphoproteomics, researchers identified that metastatic Docetaxel-resistant prostate cancer cell lines exhibit increased phosphorylation of focal adhesion kinase on Y397 and Y576, in comparison to parental controls. [Mol Cancer Ther] Abstract

Human Fucosyltransferase 6 Enables Prostate Cancer Metastasis to Bone
Overexpression of fucosyltransferase (FT)3, FT6 or FT7 restored E-selectin ligands and enabled mouse prostate cancer (PCa) cells to roll and adhere in E-selectin-functionalized microtubes, similar to trafficking of circulating PCa cells in bone marrow vessels. [Br J Cancer] Full Article

Modulators of Estrogen Receptor Inhibit Proliferation and Migration of Prostate Cancer Cells
Researchers demonstrated that raloxifen, tamoxifen, genistein and curcumin decreased DU145 and PC3 cell proliferation in a dose-dependent manner; in addition, all four compounds significantly decreased the detachment of cells seeded on laminin or fibronectin. [Pharmacol Res] Abstract

Procyanidin B2 3,3?-Di-O-Gallate, a Biologically Active Constituent of Grape Seed Extract, Induces Apoptosis in Human Prostate Cancer Cells Via Targeting NF-?B, Stat3, and AP1 Transcription Factors
Researchers synthesized gram-scale quantities of B2 3,3?-di-O-gallate (B2G2), compared it with B2G2 isolated from grape seed extract for possible equivalent biological activity and conducted mechanistic studies. Both B2G2 preparations inhibited cell growth, decreased clonogenicity, and induced cell cycle arrest and apoptotic death, comparable to each other, in various human prostate cancer cell lines. [Nutr Cancer] Abstract

The Expression of C-FABP and PPAR? and Their Prognostic Significance in Prostate Cancer
The expression levels of cutaneous fatty acid-binding protein (C-FABP) and peroxisome proliferator-activated receptor ? (PPAR?) in prostate cancer cell lines and the cytoplasm and nuclei of carcinoma tissues were significantly higher compared to those in benign cell lines and benign prostatic hyperplasia tissues. [Int J Oncol] Abstract

Context-Dependent Role of ATG4B as Target for Autophagy Inhibition in Prostate Cancer Therapy
By analyzing PC-3 and C4-2 prostate cancer cells overexpressing dominant negative ATG4BC74A in vitro and in vivo, scientists showed that the effects of ATG4BC74A are cell type, treatment, and context-dependent. [Biochem Biophys Res Commun] Abstract

Decreased c-Abl Activity in PC-3 and LNCaP Prostate Cancer Cells Overexpressing the Early Growth Response-1 Protein
To study the effect of overexpression of early growth response-1 on the activity of c-Abl in prostate cancer cells, human PC-3 and LNCaP cells were transfected with a control vector or a vector containing the murine Egr-1 cDNA and assessed for the expression of the c-Abl gene. [Oncol Rep] Abstract

Regulation of Epithelial Plasticity by miR-424 and miR-200 in a New Prostate Cancer Metastasis Model
Using an in vivo cycling strategy, scientists selected metastatic cancer cells from the lymph nodes of mice bearing orthotopic DU145 human prostate tumors. Repeated rounds of metastatic selection progressively increased the epithelial phenotype, resulting in a new model of tumor cell mesenchymal-epithelial transition. [Sci Rep] Full Article


Clinical Benefits of Non-Taxane Chemotherapies in Unselected Symptomatic Metastatic Castration-Resistant Prostate Cancer Patients after Docetaxel: The Getug P02 Study
Investigators evaluated the overall benefits of non-taxane chemotherapies in a non-selected population including unfit patients presenting with symptoms and pain. [BJU Int] Abstract

[Free Webinar] A Guide To Successful Flow Cytometry Analysis of ALDHbr Cells - Watch Now.
Clinical Use of Novel Urine and Blood Based Prostate Cancer Biomarkers: A Review
Although results appear to be encouraging, the biggest challenge about new markers in prostate cancer (PCa) is to validate them in large clinical trials and subsequently implement these markers into clinical practice. The authors discuss the clinical usefulness of novel, non-invasive tests in PCa management. [Clin Biochem] Abstract

Disruption of Prostate Epithelial Differentiation Pathways and Prostate Cancer Development
The authors review what is known about important differentiation pathways (Myc, p38MAPK, Notch, PI3K/Pten) in the prostate and how their misregulation could lead to oncogenesis. [Front Oncol] Full Article

Visit our reviews page to see a complete list of reviews in the prostate cell research field.
Emergent BioSolutions Presents Preclinical Data on ES414, Its Lead Bispecific ADAPTIR Therapeutic for Prostate Cancer
Emergent BioSolutions Inc. announced that it presented preclinical data on its lead bispecific ADAPTIRTM (Modular Protein Technology) therapeutic, ES414. The ES414 molecule was constructed using Emergent’s ADAPTIR technology platform and is being developed as a potential therapeutic for metastatic castration-resistant prostate cancer. [Emergent BioSolutions Inc.] Press Release

Mayo Study Customizing Treatments for Deadly Prostate Cancer with Tumor Genomics
A new study at Mayo Clinic is using genomic sequencing to develop customized treatments for men with castration-resistant prostate cancer, a progressive and incurable stage of prostate cancer, which no longer responds to hormone therapies that stop or slow testosterone production. [Mayo Clinic] Press Release

UPMC Expands the Use of Next-Generation Sequencing for Cancer Patients to Guide New Therapies
In a move away from a one-size-fits-most approach to treating cancer, University of Pittsburgh Medical Center (UPMC) and the University of Pittsburgh are significantly expanding capabilities to use next-generation sequencing to provide personalized care for cancer patients. [UPMC] Press Release

From our sponsor:
Looking for ALDH+ cancer stem cells? Watch a video to see how ALDEFLUORTM can help.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Molecular Medicine Tri-Conference 2014
February 9-14, 2014
San Francisco, United States

Visit our events page to see a complete list of events in the prostate cell community.
NEW Postdoctoral Fellow – Development and Progression of Prostate Cancer (University of Maryland Baltimore, School of Medicine)

Postdoctoral Fellow / Instructor Position – Endocrine Therapies for Cancer (Baylor College of Medicine)

Experienced Researcher Position – Molecular Biology (ServiceXS B.V.)

Postdoctoral Fellow – Mechanisms of DNA Damage in the Development and Progression of Prostate Cancer (Johns Hopkins Hospital)

Research Technician Position – Steroid Receptor Signaling (Baylor College of Medicine)

Postdoctoral Position – Prostate Cancer Biology (University Of Rochester School Of Medicine)

Scientist – Particle Chemistry (STEMCELL Technologies Inc.)

Research Technologist – Human Pluripotent Stem Cell Products (STEMCELL Technologies Inc.)

Research Associate/Scientist – Antibodies Group (STEMCELL Technologies Inc.)

Research Associate – Particle Chemistry (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.
Learn more about Prostate Cell News: Archives | Events | Contact Us